Trial Profile
A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2020
Price :
$35
*
At a glance
- Drugs MMV 390048 (Primary)
- Indications Falciparum malaria
- Focus Pharmacokinetics; Proof of concept
- 27 May 2020 Status changed from completed to discontinued.
- 13 Jan 2020 Results assessing safety, pharmacokinetic profile and antimalarial activity of MMV39004 to reach clinical development from trials (NCT02230579, NCT02281344 and NCT02554799) published in the Antimicrobial Agents and Chemotherapy
- 19 May 2016 Status changed from recruiting to completed.